SKYE — Skye Bioscience, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1516551 ·
Last close
$1.00
Market Cap
$4.43M
52W High
$11.20
52W Low
$0.50
ADV30
90,972
Next earnings
2026-11-16
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,973,683 69,126 5,072,591 4,815,851 3,712,182
Jun 2026 0 — -7,811,303 -10,786,594 11,033,795 8,068,357 11,531,102
Mar 2026 0 — -12,674,366 -12,509,361 19,416,736 8,149,015 10,404,932
Dec 2025 0 — -14,895,544 -14,441,963 28,313,633 5,882,498 8,289,458

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-38,810,453
Investing CF
$23,201,692
Financing CF
$-161,126
CapEx
$-6,312
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.16
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-210,170,441
Inventory
—
Receivables
$7,356
ST Investments
$1,995,784
EBIT TTM
$-50,483,680
Pretax Income TTM
$-50,489,178
Interest Exp TTM
$5,498
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -58,163,565 -55,924,814 28,313,633 8,289,458 20,024,175 -43,062,529
Dec 2024 0 -36,427,435 -26,567,123 72,763,773 4,612,049 68,151,724 -25,237,480
Dec 2023 0 -13,671,801 -37,644,784 11,940,411 14,072,229 -2,131,818 -13,952,178
Dec 2022 0 -12,106,422 -19,481,602 9,111,072 12,119,126 -3,008,054 -12,744,072

TTM Snapshot

Revenues TTM
$2,763,224
NetIncome TTM
$-50,492,578
OpCashFlow TTM
—
Assets (Latest)
$11,033,795
Forward EPS
$-6.67

Peers — same industry

TickerNameMarket CapLastDaily %
ADXN Addex Therapeutics Ltd. $4.43M $3.50 —
TCRT Alaunos Therapeutics, Inc. $4.22M $1.66 —
LTRN Lantern Pharma Inc. $4.67M $0.37 —
KPRX KIORA PHARMACEUTICALS INC $4.11M $0.93 —
CNSY CERENOME, INC. $4.78M $0.63 —

News headlines (Yahoo Finance, 1h cache)

Skye Bioscience Inc (SKYE) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Fibrex ...
2026-08-17 17:32 · Yahoo
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
2026-08-14 13:33 · Yahoo
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
2026-07-17 10:39 · Yahoo
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
2026-04-07 11:00 · Yahoo
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-12 17:33 · Yahoo
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
2026-05-11 20:01 · Yahoo
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
2026-05-20 11:00 · Yahoo
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
2026-04-02 11:00 · Yahoo
Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference
2026-03-18 05:06 · Yahoo
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...
2026-03-12 01:04 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.